Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Racura Oncology's RC220 Matches RC110 Drug Exposure in Nonclinical Bridging Study, Linking RC220 to Prior Clinical Experience in AML


      News provided by

      Racura Oncology Ltd

      Nov 17, 2026, 07:00 ET

      Share this article

      Share this article


      Exposure ratios met pre-specified equivalence criteria on all three dosing days, supporting use of the established RC110 clinical dataset and dosing levels for RC220, including in the Phase 2b/3 EMILI trial in acute myeloid leukemia

      SYDNEY, Nov. 17, 2026 /PRNewswire/ -- Racura Oncology Ltd (ASX: RAC) ("Racura" or the "Company"), a late clinical-stage biopharmaceutical company developing new small molecule-based approaches to cancer treatment focused on inhibiting MYC gene expression, today announced results from a Good Laboratory Practice (GLP) nonclinical pharmacokinetic (PK) bridging study showing that RC220, the Company's proprietary formulation of (E,E)-bisantrene, delivers systemic drug exposure equivalent to RC110, the earlier formulation used in two investigator-sponsored clinical trials in relapsed or refractory (R/R) acute myeloid leukemia (AML).

      Continue Reading
      Figure 1. RC220 and RC110 deliver equivalent exposure to (E,E)-bisantrene with repeat daily dosing. (A) Geometric mean peak plasma concentration (Cmax) of (E,E)-bisantrene after each of three once-daily intravenous doses (30-minute infusion) of RC110 or RC220 in male Beagle dogs (n = 6, two-period crossover with a five-day washout). (B) Ratio of RC220 to RC110 exposure (geometric mean ratio with 90% confidence interval) for Cmax and AUC on each dosing day. The shaded band is the pre-specified equivalence range of 0.80–1.25; a ratio of 1.00 indicates identical exposure.
      Figure 1. RC220 and RC110 deliver equivalent exposure to (E,E)-bisantrene with repeat daily dosing. (A) Geometric mean peak plasma concentration (Cmax) of (E,E)-bisantrene after each of three once-daily intravenous doses (30-minute infusion) of RC110 or RC220 in male Beagle dogs (n = 6, two-period crossover with a five-day washout). (B) Ratio of RC220 to RC110 exposure (geometric mean ratio with 90% confidence interval) for Cmax and AUC on each dosing day. The shaded band is the pre-specified equivalence range of 0.80–1.25; a ratio of 1.00 indicates identical exposure.

      In the study, conducted in Beagle dogs (n = 6), the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of RC220 to RC110 exposure for both peak plasma concentration (Cmax) and total exposure (area under the concentration–time curve, AUC) fell within the pre-specified equivalence range of 0.80–1.25 on each of three consecutive dosing days, with GMRs ranging from 0.971 to 1.057. These nonclinical data support applying the established RC110 clinical dataset and dosing levels to the clinical development of RC220, including the Phase 2b/3 EMILI trial in AML.

      Daniel Tillett, Ph.D., Chief Executive Officer of Racura Oncology, said: "This nonclinical study was designed to answer a critical question for our RC220 clinical programs: does RC220 deliver the same drug exposure as RC110? The results of this GLP PK study show the two formulations delivered equivalent exposure to (E,E)-bisantrene. The findings provide an important bridge to the clinical experience with RC110, which produced a 40% response rate in two separate clinical trials in heavily pretreated AML patients. The bridging study results support our plans to evaluate RC220 in patients with AML in the EMILI trial as well as our HARNESS and CPACS clinical programs. I wish to thank the Racura team and our study partners for the careful execution of this important work."

      Study Design and Results

      RC110 and RC220 contain the same active ingredient, (E,E)-bisantrene, and differ only in their formulation excipients. RC220 was developed to allow (E,E)-bisantrene to be given through a peripheral vein, rather than requiring a central venous line.

      The study used a two-period crossover design in which each male Beagle dog received once-daily intravenous doses (30-minute infusion) of RC110 and RC220 for three consecutive days, in random order and separated by a five-day washout, so that each animal served as its own control. Repeat daily dosing was examined because RC110 was given as a daily infusion over several consecutive days in the earlier AML trials, and the same approach is planned for RC220.

      Equivalence was assessed using the statistical approach described in US Food and Drug Administration (FDA) and European Medicines Agency (EMA) bioequivalence guidance, in which the 90% CI of the GMR must lie entirely within 0.80–1.25. All six intervals met this criterion, with the widest being 0.841–1.179 for Day 1 Cmax (Figure 1).

      The dog is a standard species for nonclinical PK and safety studies and was one of the two species used in the GLP toxicology program for RC220. The doses used were well below the level that causes harm, and no animal was harmed in the study. These results characterize drug exposure in the bloodstream of dogs; they do not measure anticancer activity. The safety and efficacy of RC220 in patients with AML remain to be established in clinical trials.

      Significance for the RC220 Clinical Programs

      RC110 was used in two investigator-sponsored clinical trials in R/R AML conducted at Sheba Medical Center, Israel. In a Phase 2 trial, RC110 given as a single agent produced an overall response rate (complete or partial responses) of 40% in 10 patients (Canaani et al., Eur J Haematol 2021). In a Phase 1b/2 trial, RC110 combined with fludarabine and clofarabine produced a response in 6 of 15 evaluable patients (Danylesko et al., Br J Haematol 2025). These results underpin Racura's plan to advance RC220 in AML through the Phase 2b/3 EMILI trial.

      RC220 is already being administered to patients through a peripheral vein in the Phase 1 CPACS solid tumor trial and the Phase 1 HARNESS lung cancer trial. While the bridging study results are not essential for these trials, they may help accelerate dose escalation or progression to later-stage trials. Racura will use the results to support regulatory submissions for AML and other clinical indications.

      About RC220 & (E,E)-bisantrene

      RC220 is a proprietary formulation of (E,E)-bisantrene designed to overcome drug solubility issues that prevent safe peripheral intravenous infusion. (E,E)-bisantrene is a clinically validated small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent transcriptional inhibition of the important cancer growth regulator MYC and downstream pathways.

      About Racura Oncology

      Racura Oncology (ASX: RAC) is a late clinical-stage biopharmaceutical company with a mission to silence cancer. Our lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent transcriptional inhibition of the important cancer growth regulator MYC. G4-binding by (E,E)-bisantrene has additional anticancer activities including inhibition of topoisomerase II and telomerase, as well as m6A RNA pathway modulation.

      Racura is advancing RC220 to address the high unmet needs of patients across multiple oncology indications, including the EMILI Phase 2b/3 trial in acute myeloid leukemia (AML), the HARNESS Phase 1 trial in combination with osimertinib in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and the CPACS Phase 1 trial in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumor patients.

      Learn more at www.racuraoncology.com.

      Forward-Looking Statements

      Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding expectations regarding clinical development and regulatory strategy and the Company's ability to deliver meaningful value to patients and shareholders. These statements relate to future events, future expectations, plans and prospects. Although Racura believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Racura has attempted to identify forward-looking statements by terminology including "believes", "estimates", "anticipates", "expects", "plans", "projects", "intends", "potential", "may", "could", "might", "will", "should", "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions. Any forward-looking statements contained in this press release speak only as of its date. Racura undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

      SOURCE Racura Oncology Ltd

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.